Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Short term Debt (2022 - 2023)

C4 Therapeutics has reported Short term Debt over the past 2 years, most recently at $10.3 million for Q2 2023.

  • For Q2 2023, Short term Debt rose 1278.0% year-over-year to $10.3 million; the TTM value through Jun 2023 reached $10.3 million, up 1278.0%, while the annual FY2022 figure was $2.3 million, N/A changed from the prior year.
  • Short term Debt for Q2 2023 was $10.3 million at C4 Therapeutics, up from $2.3 million in the prior quarter.
  • Over five years, Short term Debt peaked at $10.3 million in Q2 2023 and troughed at $750000.0 in Q1 2022.